Navigation Links
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

RICHMOND, Va., Oct. 30 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today reported results for the third quarter and nine-months ended September 30, 2008.

Recent Company Highlights

-- Follow-on Biologics Program

-- Received approval from the United Kingdom's Medicines and

Healthcare products Regulatory Agency to initiate a Phase I clinical

study for the Company's second follow-on biologic

("FOB") product candidate, INS-20. Insmed's INS-20

is a pegylated recombinant form of human G-CSF, and an FOB of the

FDA-approved product Neulasta(R), which had U.S. sales of

approximately $2.4 billion in 2007.


-- Received $3.0 million in cost recovery revenue in the third quarter

related to the expanded access program ("EAP") for

IPLEX(TM). The EAP in Italy to treat patients with Amyotrophic

Lateral Sclerosis ("ALS"), also known as Lou Gehrig's

Disease, currently includes 23 physicians and over 100 subjects have


-- Announced the presentation of clinical study results with Premacure

demonstrating IPLEX(TM) increased serum IGF-I levels into the normal

range in significantly premature infants. Premacure is developing

IPLEX(TM) as a potential treatment for Retinopathy of Prematurity

("ROP") via a Material Transfer Agreement with Insmed.

Based in part on the results of this study, Premacure intends to

initiate a phase II multicenter trial in the ROP indication during

the fourth quarter.

"We continue to execute on our business plan and efficiently advance each of our key clinical programs," said Dr. Geoffrey Allan, President and CEO of Insmed. "Our second FOB candidate, INS-20, has entered the clinic, and demonstrates further that we have the potential to be an initial entrant into the emerging U.S. FOB marketplace. In addition, we are working closely with RBC Capital Markets, our financial advisor, to aggressively pursue our strategic options for partnering and funding."

Revenues for the third quarter ended September 30, 2008 were $4.1 million, up from $1.4 million for the corresponding period in 2007. The increase was primarily attributable to a $1.6 million increase in cost recovery revenue from our EAP to treat patients with ALS in Italy and the grant receipt of $1.0 million from the Muscular Dystrophy Association supporting the IPLEX(TM) Phase 2 Myotonic Muscular Dystrophy ("MMD") trial.

The net loss for the third quarter of 2008 was $2.2 million or $0.02 per share, compared with a net loss of $3.9 million or $0.03 per share in the third quarter of 2007. This $1.7 million reduction was primarily attributable to the $2.7 million increase in revenues, which was offset by a $438,000 increase in total expenses, a $434,000 increase in net interest expense and the realization of a $54,000 non-cash loss on investments.

The $438,000 increase in total expenses was due to a $395,000 increase in research and development ("R&D expenses") and a $43,000 decrease in selling, general and administrative expenses ("SG&A Expenses").

The higher R&D Expenses were due largely to increased clinical trial activity in the current quarter compared to last year as our phase 2 IPLEX(TM) MMD trial continues to progress. SG&A Expenses were consistent quarter over quarter. Interest income for the current quarter of $78,000 was $292,000 lower than the corresponding quarter of 2007 due to a combination of the lower interest rate environment and a lower average cash balance. Interest expense of $301,000 was $142,000 higher than the same quarter in 2007 due to an increase in the debt discount amortization resulting from the quarterly payment of our 2005 convertible notes, which began in March 2008. The loss on investments arises from the write-down of our investment in Napo. This investment, which was funded by a milestone payment from Napo, was recorded as part of our agreement with Napo in 2007.

For the nine months ended September 30, 2008, revenues totaled $8.8 million, up from $5.3 million in the first nine months of 2007. Consistent with the third quarter results, the increase was primarily attributable to a $4.5 million improvement in cost recovery from our EAP to treat patients with ALS in Italy and the grant receipt of $1.0 million from the Muscular Dystrophy Association supporting the IPLEX(TM) MMD trial. This was partially offset by the absence of license income from Napo and the revenues lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our settlement agreement with Genentech Inc. and Tercica Inc., entered into in 2007.

The net loss for the nine months ended September 30, 2008 was $11.7 million, or $0.10 per share, compared to $16.7 million, or $0.15 per share, for the first nine months of 2007. Year-over-year, R&D Expenses increased to $15.8 million for the first nine months of 2008, from $14.4 million during the same period last year, reflecting an overall increase in clinical trial activity for our FOB and IPLEX(TM) programs. SG&A Expenses fell to $3.7 million for the first nine months of 2008 from $7.4 million a year earlier due to the elimination of litigation expenses following the March 2007 settlement and the removal of commercial expenses associated with our business restructuring plan.

Interest income for the first nine months of 2008 of $453,000 was a reduction from the $895,000 earned in the same period of 2007. Interest expense increased to $983,000 in the most recent nine month period from $465,000 during the corresponding period of 2007. The same factors effecting the third quarter interest movements impacted the year to date figures. The $500,000 loss on investments represents the full write down of the Napo investment during the first nine months of 2008.

As of September 30, 2008, we had total cash, cash equivalents and short-term investments on hand of $5.8 million, compared to $16.5 million on hand as of December 31, 2007. The $10.7 million decrease in cash, cash equivalents and short-term investments primarily reflects the use of $9.1 million for operating activities and a $1.7 million principal repayment of our 2005 convertible notes, which began on March 1, 2008.

Conference Call

To participate in today's 8:30 AM ET live conference call, please dial 866-831-6270 (U.S. callers) or 617-213-8858 (international callers), and provide passcode 95924014. A live webcast of the call will also be available at:

Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days beginning today at 10:30 AM ET at 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), using passcode 69712597.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the FOB market in the United States may be slow to develop or never develop, government regulation of the FOB market (in foreign countries and possibly in the United States) could be onerous or slow in developing or never develop, we may lack financial resources to complete development of product candidates or to fund the ongoing operations of the Company, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the FOB market may be unsuccessful, we may be unable to secure an appropriate business partner for our follow-on biologics business, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD


Corporate Communications Contact:

John Procter - Gibraltar Associates



Consolidated Balance Sheets

(in thousands, except share and per share data)


September 30, December 31,

2008 2007


Current assets:

Cash, cash equivalents and

short-term investments $5,771 $16,479

Accounts receivable, net 72 250

Prepaid expenses 118 244

Total current assets 5,961 16,973

Long-term assets:

Restricted cash - long term 2,095 2,095

Investments - 258

Deferred financing costs, net 92 170

Property and equipment, net - 4

Total long-term assets 2,187 2,527

Total assets $8,148 $19,500

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $1,117 $904

Accrued project costs & other 679 503

Payroll liabilities 633 631

Interest payable 15 23

Deferred rent 115 115

Deferred income 191 245

Convertible debt 2,211 2,211

Debt discount (584) (950)

Net convertible debt 1,627 1,261

Total current liabilities 4,377 3,682

Long-term liabilities:

Convertible debt 1,106 2,764

Debt discount (286) (651)

Net long-term convertible debt 820 2,113

Asset retirement obligation 2,217 2,217

Total liabilities 7,414 8,012

Stockholders' equity:

Common stock; $.01 par value; authorized

shares 500,000,000; issued and outstanding

shares, 122,315,635 in 2008 and 121,904,312

in 2007 1,223 1,219

Additional paid-in capital 341,973 341,270

Accumulated deficit (342,462) (330,759)

Accumulated other comprehensive loss:

Unrealized loss on investment - (242)

Net stockholders' (deficit) equity 734 11,488

Total liabilities and stockholders' equity $8,148 $19,500


Consolidated Statements of Operations

(in thousands, except per share data - unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Sales, net $- $- $- $423

Royalties 29 28 83 80

License income - - - 1,545

Grant revenue 1,044 - 1,044 -

Other expanded access

program income 2,998 1,368 7,713 3,212

Total revenues 4,071 1,396 8,840 5,260

Operating expenses:

Cost of goods sold - - - 576

Research and development 4,997 4,602 15,774 14,398

Selling, general and

administrative 960 917 3,739 7,381

Total expenses 5,957 5,519 19,513 22,355

Operating loss (1,886) (4,123) (10,673) (17,095)

Interest income 78 370 453 895

Interest expense (301) (159) (983) (465)

Loss on investments (54) - (500) -

Net loss $(2,163) $(3,912) $(11,703) $(16,665)

Basic and diluted net

loss per share $(0.02) $(0.03) $(0.10) $(0.15)

Shares used in

computing basic and

diluted net loss

per share 122,314 121,708 122,070 112,279


Consolidated Statements of Cash Flows

(in thousands - unaudited)

Nine Months Ended

September 30,

2008 2007

Operating activities

Net loss $(11,703) $(16,665)

Adjustments to reconcile net loss to

net cash used in operating activities:

Depreciation and amortization 813 259

Stock based compensation expense 505 227

Stock options issued for services 140 39

Realized loss on investments 500 -

Changes in operating assets and liabilities:

Accounts receivable 178 216

Inventory - 576

Other assets 126 (152)

Accounts payable 213 (6,454)

Accrued project costs 176 (514)

Payroll liabilities 2 (18)

Deferred income (54) -

Asset retirement obligation - 443

Interest payable (8) -

Net cash used in operating activities (9,112) (22,043)

Investing activities

Decreases of short-term investments 9,428 4,090

Purchases of investments - (500)

Net cash provided by investing activities 9,428 3,590

Financing activities

Proceeds from issuance of common stock

Public Offering - 18,230

Issuance costs - (1,266)

Other 62 83

Total proceeds from issuance of common stock 62 17,047

Costs incurred in conjunction with

issuance of debt - -

Other - 297

Net cash (used in) provided by

financing activities (1,596) 17,344

Decrease in cash and cash equivalents (1,280) (1,109)

Cash and cash equivalents at

beginning of period 3,554 2,121

Cash and cash equivalents at end of period $2,274 $ 1,012

The table below details the "Cash and cash equivalents" from the statement of cash flows to "Cash, cash equivalents and short-term investments" shown on the balance sheet.

September 30, December 31,

2008 2007

Cash and Cash Equivalents 2,274 3,554

Short-Term Investments 3,497 12,925

Total Cash and Cash Equivalents and

Short-Term Investments 5,771 16,479

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
2. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
3. Insmed to Seek Shareholder Approval for Reverse Split
4. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
5. Insmed to Present at Biosimilars 2008 Conference
6. Insmed to Present at BioPharm Asia 2008 Conference
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. Insmed CEO to Present at Drug Discovery & Development Conference
9. Insmed to Host Second Quarter 2008 Conference Call
10. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
11. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... October 10, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the BoxWorks conference in San Francisco. , The presentation, “Automating GxP ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):